Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | ASAP1 | CTRPv2 | pan-cancer | AAC | -0.15 | 4e-05 |
mRNA | LRRC8B | CTRPv2 | pan-cancer | AAC | 0.14 | 4e-05 |
mRNA | BAZ1B | CTRPv2 | pan-cancer | AAC | 0.14 | 4e-05 |
mRNA | HGFAC | CTRPv2 | pan-cancer | AAC | 0.13 | 4e-05 |
mRNA | SDHD | CTRPv2 | pan-cancer | AAC | -0.14 | 4e-05 |
mRNA | TULP4 | CTRPv2 | pan-cancer | AAC | 0.14 | 4e-05 |
mRNA | ERGIC3 | CTRPv2 | pan-cancer | AAC | -0.13 | 4e-05 |
mRNA | FADS2 | CTRPv2 | pan-cancer | AAC | 0.14 | 4e-05 |
mRNA | GREB1 | CTRPv2 | pan-cancer | AAC | -0.14 | 4e-05 |
mRNA | GNAZ | CTRPv2 | pan-cancer | AAC | 0.13 | 4e-05 |